USPTO Patent Grants - Organic Chemistry (C07D)

Corrosion inhibitor formulations with pyridinium and hydroxy substituents

The USPTO granted patent US12590256B2 to Saudi Arabian Oil Company on March 31, 2026, covering corrosion inhibitor formulations containing compounds with both pyridinium and hydroxy substituents. The patent includes 6 claims and covers methods of making the compounds and processes for inhibiting corrosion on metallic surfaces. Inventors include Muhammad Imran Ul-haq, Nayef M. Alanazi, Turki M. Al Abeedi, Abdullah Al-Malki, and Faisal M. Al-Mutahhar.

KRas G12C inhibitors for cancer treatment

The USPTO granted patent US12590105B2 to Eli Lilly and Company on March 31, 2026, covering 24 claims for KRas G12C inhibitors and their use in treating cancer. The patent, with application number 18255713 filed on November 24, 2021, protects specific compound formulations and methods of treatment. This grant provides Eli Lilly with enforceable intellectual property rights in the United States.

Substituted Entecavir Monophosphate Alaninamide Phenolic Esters for Hepatitis B

The USPTO granted Patent No. US12590097B2 to Beijing Junke Huayuan Med Tech Co., Ltd. on March 31, 2026, covering entecavir monophosphate alaninamide phenolic ester derivatives for hepatitis B treatment. The patent grants exclusive rights to the pharmaceutical compound for resisting hepatitis B virus. This is a routine patent grant notification.

Spiroindoline pyrrolopyrrole triones NRF2-β-TrCP inhibitors for fatty liver treatment

USPTO granted Patent US12590100B2 to researchers from Universidad Autonoma de Madrid and CSIC for spiroindoline pyrrolopyrrole trione compounds that inhibit the NRF2-β-TrCP interaction for treating fatty liver disease. The patent covers 3 claims and relates to therapeutic applications for chronic inflammation and oxidative stress-related liver conditions.

Inhibitors of histone deacetylase useful for the treatment or prevention of HIV infection

USPTO granted Patent US12590099B2 to Merck Sharp & Dohme LLC covering HDAC (histone deacetylase) inhibitors useful for treating or preventing HIV infection. The patent protects compounds of Formula I, pharmaceutical compositions thereof, and methods of treatment. Four claims were granted. The patent application was filed on November 4, 2019.

Pyrimido pyrimidinone compound and pharmaceutical composition comprising the same

The USPTO granted Patent US12590098B2 to Axceso Biopharma Co., Ltd. on March 31, 2026, covering a pyrimido pyrimidinone compound that inhibits PD-L1 expression for cancer treatment. The patent includes 9 claims and names 8 inventors including Young Jun Park and Sung Jun Park.

Imidazo[2,1-f][1,2,4]triazin-4-amine as TLR8 agonists for cancer treatment

USPTO granted Patent US12590096B2 to BeOne Medicines GmbH for an imidazo[2,1-f][1,2,4]triazin-4-amine derivative as a TLR8 agonist for treating cancers. The patent contains 18 claims and was filed on July 31, 2020 (Application No. 17632027). The compound is classified under 12 CPC codes spanning antineoplastic, antiviral, and anti-inflammatory applications.

Crystalline Forms of Orally Available Selective KIT and PDGFR Kinase Inhibitor

USPTO granted patent US12590095B2 to Sandoz AG on March 31, 2026, covering crystalline forms of avapritinib, a KIT and PDGFR kinase inhibitor. The patent (CPC C07D 487/04) protects polymorphs and hydrates of the compound for treating gastrointestinal stromal tumors (GIST) and advanced systemic mastocytosis (AdvSM). Inventors include Verena Adamer, Andrea Thaler, and Erwin Schreiner.

Compounds for the treatment of neurodegenerative and metabolic disorders

USPTO granted Patent US12590094B2 to University of Florida Research Foundation for heterocyclic compounds targeting neurodegenerative diseases linked to protein misfolding, including Alzheimer's, Parkinson's, ALS, and prion diseases, as well as metabolic disorders. The patent covers 8 lead compound series demonstrating NAD-restoring properties and therapeutic efficacy in cellular and animal models.

Indolo[2′,3′:3,4]pyrido[2,1-b]quinazoline compound and use thereof

USPTO granted patent US12590093B2 to the Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences, covering an indolo[2′,3′:3,4]pyrido[2,1-b]quinazoline compound for treating cardiovascular and cerebrovascular diseases. The patent lists 13 inventors and contains 4 claims, with applications including increasing expression of AMPK, ABCA1, and SR-BI, and inhibiting NLRP3, IL-1β, NF-κB, and MAPKs.

Antiviral agents and uses thereof

The USPTO granted Patent US12590092B2 to Griffith University for antiviral compounds of Formula (I) and pharmaceutical compositions for treating viral infections. The patent, with 21 allowed claims, names Mark Von Itzstein, Ibrahim El-Deeb, Patrice Guillon, and Larissa Heilig as inventors. Filing date was January 28, 2022.

Bristol-Myers Squibb pyrrolo TLR9 inhibitors for fibrosis, 31st Mar

Bristol-Myers Squibb pyrrolo TLR9 inhibitors for fibrosis, 31st Mar

Foghorn Therapeutics Patent for Heterocyclic Compounds Treating BAF Disorders

The USPTO granted patent US12590079B2 to Foghorn Therapeutics Inc. on March 31, 2026, covering heterocyclic compounds useful for treating BAF complex-related disorders. The patent names inventors Sabine K. Ruppel, Zhaoxia Yang, and Jason T. Lowe, with claims encompassing 20 compound variations classified under CPC codes C07D 401/14, C07D 471/04, C07D 471/10, and C07D 487/04.

Fused imidazole derivatives as GLP-1 receptor agonists for diabetes treatment

USPTO granted Patent US12590081B2 to Jiangsu Hengrui Pharmaceuticals Co., Ltd. for fused imidazole derivatives as GLP-1 receptor agonists for diabetes treatment. The patent covers 21 claims for compounds, preparation methods, and pharmaceutical compositions containing the derivatives.

Heterocyclic compound for organic electroluminescent elements

USPTO granted Patent US12590076B2 to Idemitsu Kosan Co., Ltd. for a heterocyclic compound represented by formula (1) used in organic electroluminescent elements. The patent, filed on May 10, 2019 (Application No. 17053630), contains 26 claims and covers compounds classified under CPC codes including C07D 307/91 and H01L 51/0052.

Pyrimidine-Nitrogen Bicyclic IRAK-4 Inhibitor Compound Patent

USPTO granted patent US12590090B2 to Asahi Kasei Pharma Corporation covering pyrimidine-and nitrogen-containing bicyclic compounds with IRAK-4 inhibitory activity. The patent, with 35 claims filed on September 30, 2020, protects compounds useful for prophylactic and therapeutic treatment of diseases relating to IRAK-4 inhibition.

Gilead Sciences patent for toll-like receptor modulator compounds

USPTO granted Patent US12590089B2 to Gilead Sciences covering methods for preparing toll-like receptor modulator compounds. The patent, naming 12 inventors including Andrea Ambrosi and Pavel R. Badalov, contains 7 claims relating to (R)-2-((2-amino-7-fluoropyrido[3,2-d]pyrimidin-4-yl)amino)-2-methylhexan-1-ol or salts thereof. Application No. 17673141 was filed February 16, 2022.

JAK Inhibitor Compound and Pharmaceutical Composition Patent

USPTO granted Patent US12590088B2 to Korea Pharma Co., Ltd. on March 31, 2026, covering a JAK inhibitor compound and pharmaceutical composition. The patent claims 4 items related to compounds of Formula I and their use in treating inflammatory, autoimmune, myeloproliferative diseases, and human cancers by regulating JAK kinase signal transduction.

Oxadiazole HDAC6 inhibitors and uses thereof

The USPTO granted Patent US12590084B2 to Eikonizo Therapeutics, Inc. covering oxadiazole compounds that selectively inhibit HDAC6, a protein linked to cancer and neurological disorders including Alzheimer's disease. The patent includes 20 claims and covers pharmaceutical compositions and methods of treating HDAC6-related diseases. Inventors are Florence Fevrier Wagner and Thomas Edward Richardson.

GPR139 Antagonist Patent for Depression and Neurological Disorders

USPTO granted Takeda Pharmaceutical Company Limited Patent US12590086B2 for GPR139 antagonist compounds (3-((1H-pyrazol-4-yl)methyl)-6′-(phenyl)-2H-(1,2′-bipyridin)-2-one derivatives) used in methods of treating depression, Alzheimer's disease, schizophrenia, drug addiction, sleep disorders, pain, and ADHD. The patent contains 27 claims and includes tablet formulations.

SPNS2 inhibitors patent granted to University of Virginia

USPTO granted patent US12590083B2 to the University of Virginia Patent Foundation covering SPNS2 (spinster homolog 2) inhibitor compounds and their pharmaceutical compositions for therapeutic use. The patent, with 2 claims, protects Formula I compounds and methods of treatment using these inhibitors.

Fused tricyclic drug patent granted, Mar 31

Fused tricyclic drug patent granted, Mar 31

Crystalline Salts of Plasma Kallikrein Inhibitor Patent

USPTO granted patent US12590069B2 to BioCryst Pharmaceuticals, Inc. covering crystalline salts of a plasma kallikrein inhibitor (Compound I), methods of preparation, pharmaceutical preparations, and methods of treatment. The patent (30 claims) names inventors Yahya El-Kattan and Yarlagadda S. Babu, with an August 28, 2025 filing date. This is a routine patent grant establishing intellectual property protection with no new regulatory compliance obligations.

Thyromimetics Patent - Autobahn Therapeutics

USPTO granted patent US12590072B2 to Autobahn Therapeutics, Inc. covering thyromimetic compounds for treating neurodegenerative disorders and fibrotic diseases. The patent (20 claims) names inventors Thomas von Geldern and Bradley Backes, with original filing date June 17, 2021. This is a routine patent grant notice with no compliance obligations.

Crystalline salts of plasma kallikrein inhibitor patent grant

USPTO granted BioCryst Pharmaceuticals, Inc. Patent US12590068B2 covering crystalline salts of a plasma kallikrein inhibitor (Compound I), methods of preparation, and related pharmaceutical preparations. Inventors: Yahya El-Kattan and Yarlagadda S. Babu. The patent contains 30 claims and 3 CPC classifications (C07D 231/14, A61K 9/0029, C07B 2200/13).

Adamantane derivatives as inhibitors of focal adhesion kinase

USPTO granted patent US12590070B2 to Samjin Pharmaceutical Co., Ltd. on March 31, 2026, covering novel adamantane derivatives as inhibitors of focal adhesion kinase (FAK) for pharmaceutical use. The patent includes 17 allowed claims and covers compounds, salts, stereoisomers, and pharmaceutical compositions. The invention is classified under CPC codes including C07D 239/48, C07D 401/12, and A61P 35/00 (antineoplastic agents).

Hydrazone derivative with aryl-substituted terminal amine group and use thereof

USPTO granted Patent No. US12590071B2 to Korea Institute of Science and Technology on March 31, 2026, covering hydrazone derivatives where the terminal amine group is substituted with aryl or heteroaryl groups. The patent includes 14 claims relating to compounds represented by Formulas 3 and 4, and methods of making these compounds. The patent relates to heterocyclic organic chemistry with potential pharmaceutical applications.

Process for preparation of macrocyclic chelant and metal complexes

USPTO granted patent US12590073B2 to Biophore India Pharmaceuticals Pvt. Ltd. for an improved process preparing macrocyclic chelant 2,2',2''-(10-(2-hydroxypropyl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid and its gadolinium/calcium metal complexes with purity exceeding 99.0% by HPLC. The patent names inventors Manik Reddy Pullagurla and Jagadeesh Babu Rangisetty, with 9 claims granted.

Method of fixating carbon dioxide to substituted oxazolidinones using MOF technology

USPTO granted patent US12590074B2 to King Fahd University of Petroleum and Minerals on March 31, 2026. The patent covers a method of fixating carbon dioxide (CO2) to form substituted oxazolidinones using a MIL-68(In)-X metal-organic framework (MOF) catalyst, reacting CO2 with epoxides and aromatic amines. The patent contains 20 claims and application number 18329092.

Process for the production of levetiracetam

USPTO granted Patent US12590059B2 to Suzhou BrightHope Pharmatech Co., Ltd. for a process to produce levetiracetam via crystallization in aqueous solution, resulting in a product containing no residual organic solvent. The patent lists 4 inventors (Songzhou Hu, Lijun Deng, Wen Yu, Zhen Song) and contains 13 claims under classification C07D 207/27.

Levorphanol prodrugs and processes for making and using them

The USPTO granted Patent US12590065B2 to Zevra Therapeutics, Inc. covering novel levorphanol prodrug compositions formed by chemically conjugating oxoacids, polyethylene glycols, or vitamin compounds to levorphanol. The patent includes claims to the compositions and methods of making and using them.

Fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds and use thereof

USPTO granted Patent US12590066B2 to Korea Institute of Science and Technology for novel fused-heterocyclyl-carbonohydrazonoyl dicyanide compounds. The patent includes 20 claims and names inventors Ae Nim Pae, Yun Kyung Kim, Sang Min Lim, Sungsu Lim, Haeun Lee, Woo Seung Son, and Hye Yeon Lee. The compounds have potential pharmaceutical applications.

USPTO Patent Grant: Daprodustat Crystal Form M Preparation and Use

The USPTO has granted patent US12583823B2 for a specific crystal form (crystal form M) of the drug daprodustat, a proline hydroxylase inhibitor. The patent covers the preparation method and use of this crystal form, which exhibits improved stability and solubility characteristics.

USPTO Patent Grant: Light-Emitting Element with Long Lifetime

The USPTO has granted a patent (US12588408B2) to Semiconductor Energy Laboratory Co., Ltd. for a novel light-emitting element. The patent describes an element with a long lifetime and high efficiency, utilizing specific organic acceptor and host materials in its electron-transport layers.

USPTO Patent Grant for PCSK9 Inhibitors

The USPTO has granted a patent (US12584120B2) to AstraZeneca AB for novel PCSK9 inhibitors and methods of use. The patent covers specific heteroaryl compounds that bind the PCSK9 protein, aiming to advance treatments for conditions related to cholesterol regulation.

USPTO Grants PRMT5 Inhibitors Patent to Merck Sharp & Dohme

The USPTO has granted a new patent (US12583871B2) to Merck Sharp & Dohme LLC for PRMT5 inhibitors. The patent covers compounds and methods for treating conditions such as cancer, sickle cell, and hereditary persistence of foetal hemoglobin.

Azaheteroaryl Compound Patent Granted

The USPTO has granted patent US12583870B2 to SHANGHAI BLUERAY BIOPHARMA CO., LTD. for an azaheteroaryl compound and its preparation method. This patent covers compounds and compositions for treating diseases related to EED protein and PRC2 protein complex mechanisms.

USPTO Patent Grant: PSMA Imaging Agents

The United States Patent and Trademark Office (USPTO) has granted patent US12583887B2 to Siemens Medical Solutions USA, Inc. for PSMA imaging agents. The patent covers compounds and methods for imaging prostate-specific membrane antigen (PSMA), suitable for PET and SPECT imaging.

USPTO Patent Grant US12583859B2 for PRMT5 Inhibitors

The USPTO has granted patent US12583859B2 to the California Institute of Technology for PRMT5 inhibitors. The patent covers compounds and methods useful in treating cancers and other diseases.

A2A Receptor Antagonist Salt and Crystal Forms

The USPTO has granted patent US12583869B2 for a salt form and crystal form of an adenosine A2A receptor antagonist, along with its preparation method. The patent, assigned to CSTONE PHARMACEUTICAL (SUZHOU) CO., LTD., also covers the application of these forms in preparing medicine for A2A receptor-related diseases.

USPTO Patent Grant: JAK Inhibitors Synthesis Methods

The USPTO has granted patent US12583868B2 for novel JAK inhibitors and methods for their synthesis and use, assigned to Galderma Holding SA. The patent covers compounds with formula (I) and their application in treating various diseases.

USPTO Patent Grant: Pyridone Derivative Crystal Form

The USPTO has granted a patent to Jiangxi Caishi Pharmaceutical Technology Co., Ltd. for a novel pyridone derivative crystal form and its preparation method. This patent covers specific crystal forms and their application in treating influenza, potentially offering improved efficacy and bioavailability.

USPTO Patent Grant: IAP Antagonists for Cancer Treatment

The USPTO has granted a patent (US12583866B2) to BeOne Medicines I GmbH for novel pyrido[2,3-b][1,4]oxazine or tetrahydropyrido[2,3-b][1,4]oxazepine derivatives. These compounds act as antagonists of Inhibitors of Apoptosis Proteins (IAPs) and are intended for use in treating cancer by inducing or sensitizing cells to apoptotic cell death.

Biologically Active Taxane Analogs and Oral Treatment Methods - Patent Granted

The USPTO has granted a patent (US12583865B2) to Tapestry Pharmaceuticals, Inc. for biologically active taxane analogs and methods of oral treatment for cancer. The patent covers novel chemical compounds, compositions, manufacturing methods, and combinations with other therapeutic agents.

Organic EL Device with Different Host Materials

The USPTO has granted a patent for an organic electroluminescent (EL) device. The patent describes a device with two emitting layers, each containing a different host material and a compound that emits fluorescence with a main peak wavelength of 500 nm or less. The patent specifies a condition for the triplet energy of the host materials.

USPTO Grants Patent for Nanoporous Material for Ion Channels

The USPTO has granted a new patent (US12583863B2) to the University of Wyoming for a synthetically modifiable ion channel material. This material, a nanoporous structure with controlled electronic and ion transport properties, mimics natural zeolites and MOFs.

USPTO Patent Grant for API Crystalline Form Preparation

The USPTO has granted patent US12583860B2 to Apotex Inc. for processes to prepare multicomponent crystalline forms of active pharmaceutical ingredients using solvent vapour. The patent covers methods involving mixing a solid API with a liquid or solid pharmaceutically acceptable entity in the presence of solvent vapour, utilizing standard rotary apparatus.

Genentech, Inc. Granted Patent for TDO2 Inhibitors

The USPTO has granted Genentech, Inc. patent US12583858B2 for TDO2 inhibitors. These inhibitors are useful for modulating tryptophan 2,3 dioxygenase activity, treating immunosuppression, and enhancing anti-cancer treatments. The patent was filed on October 12, 2020.

USPTO Patent US12583857B2 for Anti-liferative Agents

The USPTO has granted patent US12583857B2 for anti-liferative agents comprising substituted benzo[e]pyrido[1,2-a][1,4]diazepines. The patent was granted to PHEON THERAPEUTICS LTD and covers compounds useful as medicaments, particularly as anti-proliferative agents.

Amgen KRAS G12C Inhibitors Patent Granted

The USPTO has granted Amgen Inc. a patent (US12583854B2) for KRAS G12C inhibitors and methods of using them to treat cancers. The patent covers compositions and methods for treating pancreatic, colorectal, and lung cancers.